#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adrenogenital syndrome Myotonia Neovascular age-related macular degeneration Brain stem glioma Infective uveitis Univentricular heart Progressive supranuclear palsy Primary immunodeficiency syndrome High-grade B-cell lymphoma Glycogen storage disease type II Neuropathic arthropathy Chronic graft versus host disease in skin Tuberous sclerosis complex Cardiac arrest Glioblastoma multiforme More trials…

    Learn about Rare Diseases

    Adrenogenital syndrome Sarcoma Loeys-Dietz syndrome – Trials in Disease Waldenstrom’s macroglobulinaemia recurrent – Diagnostics Friedreich’s ataxia Castleman’s disease – Diagnostics Nodal marginal zone B-cell lymphoma Langerhans’ cell histiocytosis – Trials in Disease Soft tissue sarcoma – Basic Information Uterine leiomyosarcoma – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Risperidone Tyra-300-B01 Grwd5769 Poloxamer 407 Pp1493 Ima402 Rbp030.2 Povidone, Iodinated Naproxen Sodium Omaveloxolone Monalizumab Benzylpenicillin PUCOTENLIMAB Progesterone, Micronised Sodium Cromoglicate Triamcinolone Safinamide Sultiame Metolazone Eribulin Mesylate More therapies…

    Learn about Your Condition

    Nicotine dependence Osteosarcoma Prostate cancer recurrent Retinitis pigmentosa Aphthous ulcer Skin neoplasm excision Cardiovascular disorder Diabetic gastroparesis Polycythaemia vera Anal cancer Cardiac amyloidosis Mantle cell lymphoma recurrent Nodal osteoarthritis Relapsing multiple sclerosis Pancreatic neoplasm More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Genetic Phenomena

  • Study on the Effects of Atidarsagene Autotemcel for Patients with Late Juvenile Metachromatic Leukodystrophy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metachromatic leukodystrophy
    Investigated Drugs:
    • Atidarsagene Autotemcel
    Italy

  • Study of Atidarsagene Autotemcel for Treating Early Onset Metachromatic Leukodystrophy (MLD) in Patients

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metachromatic leukodystrophy
    Investigated Drugs:
    • Atidarsagene Autotemcel
    Italy

  • Study of Capivasertib and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer with PTEN Deficiency

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone-dependent prostate cancer
    Investigated Drugs:
    • Capivasertib
    • Abiraterone Acetate
    Belgium Bulgaria Czechia France Germany The Netherlands +3

  • Long-term Safety Study of Miransertib for Patients with PIK3CA-related Overgrowth Spectrum or Proteus Syndrome

    Not recruiting

    2 1 1
    Investigated Diseases:
    • PIK3CA related overgrowth spectrum
    • Proteus syndrome
    Investigated Drugs:
    • Miransertib
    Italy

  • Study on the Safety and Effects of PBF-999 for Patients with Prader-Willi Syndrome

    Not recruiting

    2 1
    Investigated Drugs:
    • Pbf-999
    Spain

  • Study on Tildacerfont to Reduce Glucocorticoid Use in Adults with Classic Congenital Adrenal Hyperplasia

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Adrenogenital syndrome
    Investigated Drugs:
    • Hydrocortisone
    • Prednisolone
    • Tildacerfont
    Denmark Estonia Germany Ireland Italy Latvia +6
Previous Page
1 … 3 4 5 6
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!